Results 41 to 50 of about 8,127 (167)

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro, Samuel J. Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono   +9 more
wiley   +1 more source

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

BMC Cancer
Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i).
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group   +11 more
doaj   +1 more source

UK recommendations for Ki‐67 immunohistochemical staining and interpretation in breast cancer

Histopathology, EarlyView.
Where possible, a validated digital imaging system should be utilized. If this is not available, then intermediate scores (5%–30%) should be thoroughly assessed using the Ki‐67 International Working Group guidance. Difficult cases should be double scored.
Abeer M Shaaban, Andrew Dodson, Emad Rakha, Ian Ellis, Daniel Rea, Cecily Quinn, Elena Provenzano, Sarah Pinder, on behalf of the UK National Coordinating Committee for Breast Pathology (NCCBP), Association of Breast Pathology (ABP) and the UK National External Quality Assessment Scheme for Immunohistochemistry and In Situ Hybridisation (UK NEQAS ICC & ISH)   +9 more
wiley   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Lactic acidosis, a potential toxicity from drug–drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report

Cancer Reports, 2022
Background Ribociclib, one of the cyclin‐dependent kinases (CDK) 4 and 6 inhibitors, in combination with endocrine therapies has been approved in the treatment of hormonal receptor positive, HER‐2 negative metastatic breast cancer worldwide.
Chalita Lagampan, Nattaya Poovorawan, Napa Parinyanitikul   +2 more
doaj   +1 more source

The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi, Maria Carmen Affinita, Giulia Fichera, Luisa Santoro, Angela Scagnellato, Calogero Virgone, Elena Poli, Gianni Bisogno   +7 more
wiley   +1 more source

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Health Economics Review, 2023
Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC).
Ali Darvishi, Rajabali Daroudi, Ali Akbar Fazaeli   +2 more
doaj   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source

Can Kisqali® (Ribociclib) effectively target triple-negative breast cancer? A computational insight on potential mechanisms and therapeutic strategies

Discover Chemistry
Triple-negative breast cancer (TNBC), which represents 15–20% of all breast cancers, is a highly aggressive subtype distinct by the absence of estrogen, progesterone, and HER2 receptors, with few targeted therapies available.
Ansari Vikhar Danish Ahmad, Mohd Sayeed Shaikh, Qazi Yasar   +2 more
doaj   +1 more source

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

Therapeutic Advances in Medical Oncology, 2022
Introduction: The MONALEESA-7 trial compared ribociclib plus endocrine therapy (ET) with placebo as first-line treatment of advanced luminal/HER2-negative breast cancer (ABC) in premenopausal and perimenopausal women (age
Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Sergio D. Simon, Gilberto Amorim, Tomás Reinert, Luciana Landeiro, Débora de Melo Gagliato, Pedro Exman, Daniel Argolo, Gisah Guilgen, Max Mano, Laura Testa, Pedro Liedke, Romualdo Barroso, Mariana Sasse, Anna Maria Buehler   +15 more
doaj   +1 more source